Oncomine Cell-Free DNA Assay is designed to target and detect mutations down to 0.1 percent allele frequencies from whole blood derived from lung cancer tumors
Studies show droplet volume liquid biopsy detects new tumor mass earlier than current imaging methods and detects more mutations than tissue biopsy
SelectScience® spoke to Rebecca Gentile, Senior Specialist in Quality, Vaccine and Biological Stability at Merck, about the future and current challenges of her work
Project that measured pathogens in New York City subways goes global this summer
Learn how to streamline your sample and data management
Cellca’s cell line and upstream process development services now integrated
Watch interviews from industry experts at this year’s American Association of Cancer Research (AACR) Annual Meeting
Key opinion leaders’ expertise to guide design of new gene panels for GeneReader NGS
Actionable Insights Tumor Panel enables monitoring of cancer biomarkers from plasma samples
Siemens Healthineers will expand its portfolio with molecular testing related services and technologies for oncology and genomics
Gilson focus on development of the Internet of Things
Learn about the latest technologies showcased at this year’s Pittcon!
Vitrification provides excellent survivability of embryos and oocytes through the freezing process
Interlab comparison demonstrates Circulogene’s blood-drop-volume liquid biopsy assay is fastest, most accurate process to date for tracking and treating cancer
